Document is current
Any future updates will be listed below
-
Authors
Kamber, Roarke A.
Nishiga, Yoko
Morton, Bhek
Banuelos, Allison M.
Barkal, Amira A.
Vences-Catalán, Felipe
Gu, Mingxin
Fernandez, Daniel https://orcid.org/0000-0002-6221-152X
Seoane, Jose A. https://orcid.org/0000-0002-3856-9177
Yao, David
Liu, Katherine
Lin, Sijie
Spees, Kaitlyn
Curtis, Christina
Jerby-Arnon, Livnat https://orcid.org/0000-0002-4037-386X
Weissman, Irving L. https://orcid.org/0000-0002-9077-7467
Sage, Julien https://orcid.org/0000-0002-8928-9968
Bassik, Michael C. https://orcid.org/0000-0001-5185-8427
- License Information
-
More Information
Article History
Received: 14 October 2020
Accepted: 5 August 2021
First Online: 8 September 2021
Competing interests
: R.A.K. and M.C.B., through the Office of Technology Licensing at Stanford University, have filed a patent application on the methods and findings in this manuscript. I.W. is an inventor on several patents in the field of ADCP induced by blockade of several don’t-eat-me signals such as CD47, CD24, beta-2-microglobulin, and PDL1, and their macrophage cognate receptors, respectively, SIRPα, Siglec-10, LILRB1, and PD1. These have been licensed to several companies. I.W. is not currently affiliated with these companies and does not hold stock in them. He is, however, engaged in the formation of one or more start-up companies in the field. J.S. licensed a patent to Forty Seven Inc./Gilead on the use of CD47 blocking strategies in SCLC.
